Swiss biotechnology company Selexis SA, which specializes in the creation of stable cell lines for the production of therapeutic proteins, says that it is to develop its manufacturing facilities and business operations. The firm added that it has already carried out expansion of its administrative offices and its manufacturing plant, the size of which has increased by 4,305 square feet.
Selexis said that, during 2006, its client base had grown 100%, and added that this included a record number of license renewals. The firm also said that further development of its facilities would enable it to provide the best possible service for its customers, and would form the basis for future corporate growth.
The company added that expansion would allow further improvement of its Sure Cell Line-based technology and associated services.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze